Dr James AllanSenior Lecturer
Email: james.allan@ncl.ac.uk Telephone: +44 (0) 191 246 4435 Fax: +44 (0) 191 246 4301 Address: Northern Institute for Cancer Research
Fordham SE, Marr H, Allan JM. Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognostication .
Leukemia and Lymphoma 2013, 54 (3), 447-448.
Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia .
Blood 2012, 119 (1), 196-205.
Forster V, Beyerle A, Heidenreich O, Allan J. AML1/ETO Confers a Mutator Phenotype in AML .
In: Annual Meeting of the Kind-Philipp Foundation for Leukemia Research . 2012, Wilsede, Germany: Georg Thieme Verlag.
Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Tomlinson IPM, Allan JM, Taylor M, Greaves M, Houlston RS. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia .
Leukemia 2012, 26 (10), 2212-2215.
Allan J, Sniehotta F, Johnston M. Good planners can already plan but poor planners benefit from action plans .
In: “Resiliance and Health” : 26th Conference of the European Health Psychology Society . 2012, Prague, Czech Republic: Routledge.
Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy .
Journal of the National Cancer Institute 2012, 104 (5), 357-370.
Fordham SE, Matheson EC, Scott K, Irving JAE, Allan JM. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs .
Leukemia 2011, 25 (6), 1046-1049.
Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia .
In: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, FL: Blood: American Society of Hematology.
Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow L, Jackson G, Bomken S, Jones G, Allan JM. A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia .
In: Blood: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, Florida, USA: American Society of Hematology.
Pratt G, Fenton JAL, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JAE, Allan JM. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma .
British Journal of Haematology 2010, 150 (3), 371-373.
Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine Is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia .
In: Blood: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, Florida, USA: American Society of Hematology.
Fordham SE, Matheson EC, Scott K, Irving J, Allan JM. Cellular Response to Cytarabine is Modulated by the DNA Mismatch Repair Pathway: Implications for Treatment of Acute Myeloid Leukemia .
In: Blood: American Society of Hematology Annual Meeting . 2010, Orlando, Florida, USA: American Society of Hematology.
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, Dyer MJS, Matutes E, Dearden C, Sunter NJ, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan JM, Catovsky D, Houlston RS. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk .
Nature Genetics 2010, 42 (2), 132-136.
Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, Smith MT, Allan JM, Taylor GM, United Kingdom Childhood Cancer Study. Genetic variation in the folate metabolic pathway and risk of childhood leukemia .
Blood 2010, 115 (19), 3923-3929.
Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS. Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk .
Blood 2010, 115 (22), 4472-4477.
Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Fowler TM. Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia .
In: Blood: 52nd Annual Meeting of the American Society of Hematology (ASH) . 2010, Orlando, Florida, USA: American Society of Hematology.
Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Mainou-Fowler T. Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia .
In: Blood: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, Florida, USA: American Society of Hematology.
Kane EV, Painter D, Roman E, Allan J, Law G, Lightfoot T. Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma .
Cancer Epidemiology 2010, 34 (2), 136-141.
Hosking FJ, Leslie S, Dilthey A, Moutsianas L, Wang Y, Dobbins SE, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Taylor M, Greaves M, McVean G, Houlston RS. MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukaemia .
Blood 2010, 117 (5), 1633-1640.
Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma .
British Journal of Haematology 2010, 149 (2), 258-262.
Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD. Testicular Cancer Survivorship: Research Strategies and Recommendations .
Journal of the National Cancer Institute 2010, 102 (15), 1114-1130.
Forster VJ, Allan JM, Heidenreich O. The t(8,21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia .
In: Blood: 52nd Annual Meeting of the American Society of Hematology . 2010, Orlando, Florida, USA: American Society of Hematology.
Forster VJ, Allan JM, Heidenreich O. The t(8;21) Fusion Protein AML1/ETO Promotes Susceptibility to Mutation In Acute Myeloid Leukemia .
In: Blood: American Society of Hematology Annual Meeting . 2010, Orlando, Florida, USA: American Society of Hematology.
Allan JM, Sunter NJ, Bailey JR, Pettitt AR, Harris RJ, Pepper C, Fegan C, Hall AG, Deignan L, Bacon CM, Pointon JC, Houlston RS, Broderick P, Mainou-Fowler T, Jackson GH, Summerfield G, Evans PA, Strefford JC, Parker A, Oscier D, Pratt G, Allsup DJ. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia .
Leukemia 2010, 24 (4), 877-881.
Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Neira AG, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk .
Nature Genetics 2010, 42 (6), 492-494.
Allan JM. [Meeting Abstract] DNA repair dysfunction and genomic instability in therapy-related malignancy .
Mutagenesis 2009, 24 (6), 530.
Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MKB, Quirke P, Seymour MT. Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial .
Journal of Clinical Oncology 2009, 27 (33), 5519-5528.
Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, Tennant TR, Banerjee M, Allan JM, Le Beau MM, Larson RA, Graubert TA, Cox NJ, Onel K. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility .
Blood 2009, 113 (22), 5575-5582.
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia .
Nature Genetics 2009, 41 (9), 1006-1010.
Worrillow L, Roman E, Adamson PJ, Kane E, Allan JM, Lightfoot TJ. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma .
Cancer Epidemiology 2009, 33 (3-4), 257-260.
Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, Larson RA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibilityBlood 2008, 112 (3), 741-749.
Allan JM, Sunter N, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris RJ, Pettitt A, Houlston R, Bailey J, Pepper C, Fegan C, Pratt G, Allsup DJ. A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia .
In: Blood: 50th Annual Meeting of the American Society of Hematology . 2008, San Francisco, California, USA: American Society of Hematology.
Onel K, Knight JA, Skol AD, Tennant TR, Banerjee M, Walgren R, Shao J, Allan JM, Le Beau MM, Larson RA, Graubert T, Cox NJ. A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia .
In: Blood: 50th Annual Meeting of the American Society of Hematology . 2008, San Francisco, California, USA: American Society of Hematology.
Di Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall AG, Dyer M, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston R. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia .
Nature Genetics 2008, 40 (10), 1204-1210.
Allan JM. Genetic susceptibility to radiogenic cancer in humans .
Health Physics 2008, 95 (5), 677-686.
Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM. Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians .
Haematologica 2008, 93 (10), 1597-600.
Ryk C, Routledge MN, Allan JM, Wild CP, Kumar R, Lambert B, Hou S. Influence of DNA repair gene polymorphisms on the initial repair of MMS-induced DNA damage in human lymphocytes as measured by the alkaline comet assay .
Environmental and Molecular Mutagenesis 2008, 49 (9), 669-675.
Allan JM , Shorto J, Adlard J, Bury J, Coggins R, George R, Katory M, Quirke P, Richman S, Scott D, Scott K, Seymour M, Travis LB, Worrillow LJ, Bishop DT, Cox A. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer .
International Journal of Cancer 2008, 123 (10), 2456-2459.
Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma .
Journal of Medical Genetics 2008, 45 (3), 142-146.
Howard R, Gilbert E, Lynch C, Hall P, Storm H, Holowaty E, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa S, Allan JM, Travis L. Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients .
Annals of Epidemiology 2008, 18 (5), 416-421.
Allan JM. The Genetics of Cancer Survivorship .
Hematology/Oncology Clinics of North America 2008, 22 (2), 257-269.
Smith AG, Worrillow LJ, Allan JM. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia .
Blood 2007, 109 (3), 1233-1236.
Worrillow LJ, Allan JM. Deregulation of homologous recombination DNA repair in alkylating agent-treatedstem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia .
Oncogene 2006, 25 (12), 1709-1720.
Allan JM, Rabkin CS. Mechanisms of therapy-related carcinogenesis .
Pharmacogenomics 2005, 6 (6), 615-628.
Allan JM, Smith AG, Wheatly K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy .
Blood 2004, 104 (13), 3872-3877.
Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, Holowaty EJ, Kohler BA, Wiklund T, Pukkala E, Roman E, Morgan GJ, Allan JM. An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents .
Clinical Cancer Research 2003, 9 , 3012-3020.
Allan JM, Hardie LJ, Briggs JA, Davidson LA, Watson JP, Pearson SB, Muers MF, Wild CP. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer .
International Journal of Cancer 2001, 91 (3), 359-365.
Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roman E, Cartwright RA, Morgan GJ. Polymorphism in glutathione S-transferase PI is associated with susceptibility to chemotherapy-induced leukaemia .
Proceedings of the National Academy of Sciences of the United States of America 2001, 98 (20), 11592-11597.
